Understanding the anti-tumour immune response to radionuclide therapy using PSMA targeting radiopharmaceuticals in a prostate cancer model
<p>The ability of external beam radiation (EBRT) to modulate the tumour immune microenvironment is becoming increasingly well understood, leading to the development of combinatorial EBRT and immunotherapeutic combinations to improve patient responses. Despite this, there is very limited unders...
Autor principal: | Anderson, R |
---|---|
Outros Autores: | Vallis, K |
Formato: | Tese |
Idioma: | English |
Publicado em: |
2021
|
Assuntos: |
Registros relacionados
-
Recent Progress of Functionalized PSMA in Radionuclide Targeted Therapy for Prostate Cancer
por: REN Ya'nan, et al.
Publicado em: (2020-12-01) -
Lead-212 Radiopharmaceuticals for Receptor-Targeted Radionuclide Therapy
por: Solmaz Mojarad-Jabali, et al.
Publicado em: (2025-01-01) -
Radiopharmaceuticals: From Molecular Imaging to Targeted Radionuclide Therapy
por: P. August Schubiger, et al.
Publicado em: (2004-10-01) -
Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review
por: Paweł Szponar, et al.
Publicado em: (2023-11-01) -
Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis
por: Alessio Rizzo, et al.
Publicado em: (2022-11-01)